Dementia and Alzheimer Disease

The published data provided preliminary evidence that AMX0035 engages Alzheimer disease pathology and pathways of neurodegeneration, synaptic function, gliosis, and oxidative stress.

Investigational drug CT1812 showed potential to improve neurophysiological markers in mild-to-moderate Alzheimer's disease, with notable EEG changes observed in a recent phase 2 study.

Steve Herne, chief commercial officer at Unlearn, provided context on a recently conducted study assessing the company’s digital twin methodology AI tool to enhance the statistical certainty of Alzheimer trials.

William Hu, MD, PhD, FAAN, a neurologist at RWJBarnabas Health’s Robert Wood Johnson University Hospital in New Brunswick, NJ, shared new advances to detect and treat Alzheimer disease.

The director of academic clinical research at Orlando Health reflected on the journey of a blood test for traumatic brain injury to clinical use, highlighting the collaborative efforts and patient participation that made it possible. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 23, 2024.

The director of academic clinical research at Orlando Health talked about applying Abbott's blood test for suspected mild traumatic brain injury, providing results within 15 minutes, in the clinical practice. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD. [LISTEN TIME: 20 minutes]

The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]

The professor of human genetics at the University of Miami discussed the significance of various genetic factors in Alzheimer risk and highlighted ongoing research, therapeutic challenges as well as the need for global collaboration. [WATCH TIME: 10 minutes]

The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.

The professor of human genetics at the University of Miami talked about the Alzheimer's Disease Sequencing Project which aims to provide diverse genetic data to identify therapeutic targets for Alzheimer disease. [WATCH TIME: 10 minutes]

The chairman and chief executive officer at Biomed provided insight on the hypothesis behind a new phase 3 study assessing NA-831, an agent with neurogenesis effects, with lecanemab, a previously approved drug for Alzheimer disease. [WATCH TIME: 7 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of frontotemporal dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 16, 2024.

Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.

The CEO and cofounder at Advanced Brain Monitoring talked about a study presented at AAIC 2024 that explored the use of EEG biomarkers to differentiate between Alzheimer disease and frontotemporal dementia.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 9, 2024.

Anavex Life Sciences intends to submit a full regulatory application for blarcamesine as a potential treatment for AD in Europe by Q4 2024.

Catch up on any of the neurology news headlines you may have missed over the course of July 2024, compiled all into one place by the NeurologyLive® team.

The positive data from this Phase 1a trial will inform the dosing for the upcoming Phase 1b portion in patients with AD, expected to commence in the second half of 2024.

The personalized medicine lead at Linus Health provided clarity on a new outcome measure that captures various perspectives about what matters to individuals and their brain health.

Treatment of the first randomized patient with preclinical Alzheimer disease in the phase 2b ReTain trial assessing JNJ-2056 is anticipated in the third quarter of 2024.

The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen provided perspective on the promising development of BIIB080, a treatment thought to work by reducing forms of tau protein. [WATCH TIME: 4 minutes]